1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Idiopathic Pulmonary Fibrosis Market - Global Opportunity Analysis and Industry Forecast, 2017-2023

Idiopathic Pulmonary Fibrosis Market - Global Opportunity Analysis and Industry Forecast, 2017-2023

  • September 2017
  • 150 pages
  • ID: 5139387
  • Format: PDF
  • By Allied Market Research

Summary

Table of Contents

Idiopathic Pulmonary Fibrosis Market by Type of Drug (Pirfenidone, Nintedanib) and Region (North America, Europe, Asia-Pacific, and LAMEA) - Global Opportunity Analysis and Industry Forecast, 2017-2023

Idiopathic pulmonary fibrosis is a condition in which the tissues in the lungs become thick and stiff over time. As a result of thickening of lung tissues, brain and other organs are unable receive optimum oxygen.

The global idiopathic pulmonary fibrosis market generated $1,616 million in 2016, and is projected to reach $3,569 million by 2023, registering a CAGR of 11.9% during the study period. The major factors that drive the growth of the global idiopathic pulmonary fibrosis market include rise in prevalence of fibrotic disease and increase in geriatric population. In addition, surge in demand for cost-effective drugs and introduction of advanced treatment options propel the market growth. However, unavailability of the proper treatment options of the disease restricts the market growth.

The global idiopathic pulmonary fibrosis market is segmented on the basis of type of drug and region. According to type of drug, the market is divided into pirfenidone and nintedanib. Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS
The report provides an in-depth analysis of parent market trends, macro-economic indicators, and governing factors.
This report provides an extensive analysis of the current and emerging market trends and dynamics in the market from 2016 to 2023 that helps identify the upcoming market opportunities.
Recent industry trends and developments and the future opportunities are also covered.
Extensive knowledge about the key market players and their strategies is provided.
Comprehensive analysis of the various factors that drive and restrain the growth of the market is provided.

Key Market Segments

By Type of Drug
Pirfenidone
Nintedanib

By Region
North America
U.S.
Canada
Mexico
Europe
France
Germany
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA

Key market players

The key players operating in this market include
MediciNova, Inc.
Boehringer Ingelheim
F. Hoffmann-La Roche
FibroGen, Inc.
Promedior, Inc.
Merck & Co., Inc.
Galapagos NV
Biogen
Bristol-Myers Squibb Company
Prometic Life Sciences Inc.
Cipla Inc.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Pipeline Review, H2 2019

Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Pipeline Review, H2 2019

  • $ 2000
  • November 2019

Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Granulomatosis with Polyangiitis (Wegener Polyangiitis) ...

Ependymoma - Pipeline Review, H2 2019

Ependymoma - Pipeline Review, H2 2019

  • $ 2000
  • November 2019

Ependymoma - Pipeline Review, H2 2019SummaryThis latest Pharmaceutical and Healthcare disease pipeline guide Ependymoma - Pipeline Review, H2 2019, provides an overview of the Ependymoma (Oncology) pipeline ...

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline Review, H2 2019

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline Review, H2 2019

  • $ 2000
  • November 2019

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline ...


ref:plp2017

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on